Drug Profile
Research programme: autologous diabetes cell therapy - Orgenesis
Alternative Names: AIP cells - Orgenesis; Autologous insulin producing cells - OrgenesisLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Tel Hashomer Medical Research Infrastructure and Services
- Developer Orgenesis
- Class Antihyperglycaemics; Cell therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus; Type 1 diabetes mellitus
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (Intra-abdominal, Implant)
- 28 Mar 2023 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (Intra-abdominal, Implant)
- 13 May 2020 Preclinical development is ongoing in USA